DWAH Stem Cell Therapy.
From:Dundas West AHViews:1 0ratingsTime:03:53More inPets Animals

Read the original here:
DWAH Stem Cell Therapy. - Video

ZUTPHEN, the Netherlands, November 20, 2012 /PRNewswire/ --

Ghent University and Cryo-Saves collaboration overcomes the restrictions encountered in bone tissue engineering of large size bone grafts. This traditional tissue engineering (TE) is often limited to the outside region resulting in a localized, non-uniform tissue formation. For the present study, Cryo-Save provided cryopreserved stem cells that show promising results to obtain a uniform cell distribution and a high cell density in the centre of bone grafts. This will improve bone deficit treatments for large size bone grafts.

Cryo-Save, Europes leading family stem cell bank, participated in a high-level tissue engineering study, headed by Dr. Heidi A. Declercq, PhD and her team from Ghent University (group leader, Prof. Dr. M. Cornelissen), Belgium, on new practices to build artificial bone tissue with stem cells. Close collaboration between Cryo-Save and Ghent University led the company to manufacture and provide cryopreserved stem cells derived from adipose tissue (ADSC) for the study. The article "Bone grafts engineered from human adipose-derived stem cells in dynamic 3D-environments" was recently published in Biomaterials, one of the most widely read and influential scientific journal in the field of Tissue Engineering and Biomaterials.

Thanks to the work of Dr. Declercq, modular tissue engineering offers an innovative way to create large bone grafts obtained with ADSC-seeded on microcarriers in a bottom-up approach. The strategy aims to engineer small volume, high-quality microtissues and the subsequent assembly in-vitro or in-vivo into larger tissue constructs upon implantation. In this study, ADSC-seeded microcarriers were exploited to prepare modular tissues (microtissues) as building blocks followed by self-assembling into macrotissues in-vitro. As a result, Dr. Declercq demonstrated that ADSC are as good as bone marrow in bone tissue engineering application revealing similar morphology, calcification level and osteogenic genes expression but the use of ADSC can substitute the painful collection of bone marrow stem cells.

The outcomes of the study are very promising for treatment of bone deficits. Dr. Declercq sees great hopes in bone tissue engineering and says: "Modular tissue engineering is a promising approach to create large bone grafts as it encounters most of the limits in traditional tissue engineering. Moreover, the combination of adipose-derived stem cells in this bottom-up approach is excellent because adipose-derived stem cells are a great source for tissue engineering purposes. A high amount of cells with high proliferation and differentiation capacity can be obtained from abundant adipose tissue sources".

Cryo-Save is thrilled to have played a major role by providing cryopreserved ADSC for use in this study. It is an integral part of Cryo-Saves activities to support research and to collaborate with leading universities, physicians and stem cell scientists, with the aim to improve clinical applications.

Cryo-Save, the leading international family stem cell bank, stores more than 225,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and South Africa.

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save Group N.V.

More:
Bone Tissue Engineering Study Led by Ghent University Improves Treatment of Bone Deficits Using Cryo-Save Stem Cells

cord blood registry | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com These diseases include blood related, genetic and neurotic disorders. ""Banking the umbilical cord blood when your baby is born is a relatively new idea, the first operation using it to help cure a child with Leukemia was only done a little over 10 years ago. After processing of cells, comes the next procedure of cord blood preservation. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. With people not fully understanding how important stem cells could be for us, everybody agrees that more research need to be done in order to help understand all that. If there is any complication during delivery, the entire idea is abandoned. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. You are injecting the patient with those same cells that created him!This can be done with the bone marrow transplants tooYes, stem cells are found in bone marrows too. It is a simple and ...From:luisantafeViews:0 0ratingsTime:01:31More inScience Technology

Continued here:
cord blood registry | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Stem cells achieve sustained heart function improvement in heart attack patients
From Louisville - Stem cell therapy has been shown to sustain heart function improvement in heart attack patients in a phase 1 clinical presented at the AHA #39;s Scientific Sessions. The trial, known as SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, randomized 33 patients diagnosed with heart failure after suffering a heart attack to either cardiac stem cells or no stem cells. Researchers found that patients who received the stem cells had great improvement in their heart function, and that this improvement was sustained 2 years following infusion. Patients who did not receive stem cells had no improvement. There were no adverse effects of the treatment. One patient #39;s heart experienced such dramatic improvement that there was no sign of heart failure at all. Said Dr. Roberto Bolli, lead author of the study, "Anyone who looks at his heart now would not imagine that this patient was (ever) in heart failure or that he had a heart attack."From:insidermedicineViews:0 0ratingsTime:00:59More inScience Technology

The rest is here:
Stem cells achieve sustained heart function improvement in heart attack patients - Video

One Gold
Get the best offer here redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fdp%2FB0079QLQ0G Product Description One Gold Experience the Anti-Aging Power of the New Generation 24K Nano Gold Stem Cell Therapy Mask. This excellent product by BeautyMedica Lab offers an innovative Transdermal Delivery System with a unique blend of transforming growth factors (TGF), amino acids, antioxidants and peptides.Sheet form of the mask makes it extremely easy to apply to the face and allowing the ingredients to be absorbed into the skin slowly melting under body temperature. The Mask was formulated to Re-activate stem cells and stimulate new skin development. Increase collagen production and elastin synthesis. Minimize appearance of fine lines and wrinkles. Enhance moisture with Y-PGA and refine skin structure. Whiten the skin and reduce melanin. Restore youthful healthy looking skin and creates radiant skin appearance.For more info, please visit 24K Gold Mask presentation video by Beauty Medical Laboratorys - http://www.youtube.comFrom:Pricilla DuongViews:0 0ratingsTime:00:58More inScience Technology

Excerpt from:
One Gold - Video

Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy for Parkinson #39;s Disease is still under research and study. However, there are impressive results by patients using oral placenta as stem cell therapy for their Parkinson #39;s disease. An 81 years old Asian with Stage 2 Parkinson #39;s disease observed cessation of tremor after only 4 weeks of oral placenta stem cell therapy. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:118 2ratingsTime:11:49More inScience Technology

Read the rest here:
Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia - Video

New technique to deliver stem cell therapy may help damaged eyes regain their sight
Engineers at the University of Sheffield have developed a new technique for delivering stem cell therapy to the eye which they hope will help the natural repair of eyes damaged by accident or disease.From:ResearchatSheffieldViews:0 0ratingsTime:01:31More inScience Technology

Continue reading here:
New technique to deliver stem cell therapy may help damaged eyes regain their sight - Video

NeoStem, Inc. (NYSE:NBS ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)", grant number 2R44DE022493-02A1, from the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). This peer reviewed grant is to support a Phase 2 investigation and first approved NIH clinical study of VSELsTM in humans. The study will be headed by Denis O. Rodgerson, Ph.D., Director of Grants and Academic Liaison for NeoStem, in collaboration with co-investigators Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment for this study is expected to begin in 2013.

This award will fund the evaluation of VSELTM stem cells as a potential treatment for periodontitis. The product candidate, an autologous therapy derived from a patient's own stem cells, is to be developed for use in the regeneration of bone tissue damaged by this disease. The award includes $706,682 for the first year and $515,172 for the second year of the project, and will cover the cost of the Investigational New Drug (IND) submission to the FDA for the product candidate.

Dr. Denis O. Rodgerson, Director of Grants and Academic Liaison for NeoStem, said, "We are pleased and honored that NIH has agreed to support further studies on bone regeneration by using VSELTM stem cells. This is an extension of our successful NIH funded collaboration with Dr. Taichman showing the production of human bone from human VSELsTM in a mouse model."

Periodontal disease is prevalent in the U.S. and affects up to 90% of the world population. The most severe cases of periodontal disease affect between 5% and 15% of the U.S. population, or between 15 and 47 million Americans. The incidence of periodontal disease is estimated to be between 1 and 3 million Americans annually, and growing at a 7% rate each year. Studies have shown that periodontal inflammation could have a role in the initiation or progression of coronary heart disease and stroke. Market research experts have estimated that severe periodontal disease represents a market between $1.25 and $1.5 billion annually.

Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership, Department of Periodontics & Oral Medicine, University of Michigan stated, "I am thrilled for the possibilities that this award opens. The chance to continue to partner with NeoStem to further develop regenerative therapies is significant. The validation that this award brings and the opportunity to establish a proof of concept, which may impact human health, is truly rewarding." Dr. Laurie McCauley, The William K. and Mary Anne Najjar Professor, Division of Periodontics Department of Periodontics and Oral Medicine, University of Michigan added, "This novel cell based therapeutic approach looks to validate scientifically sound pre-clinical studies and provide a vital translation to improved human patient care."

NeoStem has a worldwide exclusive license to VSEL technology which uses very small embryonic-like stem cells, a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. NeoStem has shown that very small embryonic-like stem cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what it believes to be an important population of stem cells that may have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative biological effects associated with embryonic stem cells.

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are very excited about this important step of funding for what will be the first human clinical study for our VSELTM technology. Not only will this study expand our knowledge of how autologous cell therapy can treat periodontitis and other bone defects, but it represents a milestone for NeoStem as we move our development of VSELTM technology beyond animal models and into the clinic, paving the way for other potential VSELTM trials."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

Excerpt from:
NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans

MANILA, Philippines - A ranking official of the Catholic Bishops Conference of the Philippines (CBCP) considers immoral the embryonic stem cell therapy reportedly being used by politicians and actors for aesthetic purposes.

In an interview with Radio Veritas, CBCP-Episcopal Commission on Bioethics Chairman and Malolos Bishop Jose Oliveros said this medical procedure is against the belief of the Church. He said they are still assessing if the same could be said for stem cells from animals.

Pero yung sinasabi nila na pampabata sa mga politician at celebrities na sumailalim sa stem cell therapy ay immoral. Puwede namang ma-improve ang mukha ng isang tao, but it should be moral. Kapag gumamit ka ng immoral ay mali na yun, he said.

Embryo is still a maturing fetus.

He said the CBCP will come out with a pastoral statement regarding the matter once they are able to clarify certain matters with the Department of Health (DOH).

The DOH earlier warned people from using stem cells from aborted babies and human embryos.

The Philippine government will not allow the use of aborted fetuses or human embryosThere is a need to ensure that the biological raw materials are documented and validated and follow infection-free procedures, the DOH earlier said.

There is also a need to know if the materials to be injected came from animal or human tissues, it added.

Read the rest here:
Stem cell therapy is immoral - bishop

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Medistem ( PINKSHEETS : MEDS ) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board.Dr. Gershman is an internationally-renowned opinion leader in urological surgery having pioneered numerous minimally invasive procedures using laparoscopic techniques.

"The future of regenerative medicine lies not only in having the best stem cell product, but also being able to practically deliver it in a manner that can be integrated into existing medical practice,"said Dr. Alan Lewis, CEO of Medistem. "Through working with respected physicians such as Dr. Gershman, our aim is to develop novel delivery methods so that our cellular product can be utilized in numerous disciplines."

Medistem is currently running a Phase II clinical trial in heart failure patients using its Endometrial Regenerative Cell (ERC) product delivered through a 30-minute minimally invasive patent pending procedure.The company seeks to develop similar minimally invasive procedures for the field of urology in collaboration with Dr. Gershman.

"It is obvious that stem cell medicine is the future of medicine.Although great strides have occurred in clinical entry of stem cells, a major hurdle to commercialization is practical implementation,"said Dr. Gershman. "I commend Medistem for having discovered what appears to be the most potent blood vessel generating stem cell, the ERC, as well as having the foresight to think practically about optimum methods of delivery."

Dr. Gershman is one of the first surgeons in the world to apply the method of laparoscopic surgery and robotic-assisted surgery to urology.He currently holds numerous hospital appointments, including the following: Director of Institute of Advanced Urology at the Cedars-Sinai Medical Center; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center; Head of Endourology Division, Department of Surgery, VA Greater Los Angeles Healthcare System; Attending Surgeon, Laparoscopic Renal Transplant Surgery, St. Mary Medical Center; Attending Surgeon at the Cedars-Sinai Medical Center; and Attending Surgeon at the Harbor-UCLA Medical Center.

About Medistem Medistem Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.

ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.

Cautionary Statement This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Read more here:
Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v
http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:0 0ratingsTime:00:55More inScience Technology

Here is the original post:
Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video

What Are Stem Cells and Stem Cell Therapy Stemenhance
http://www.stemcellproduct.net This video gives you the definition, facts, and understanding on what are stem cells, that there are two of them embryonic and adult stem cells, how they work and the uses of stem cell when the tissue is affected in your body and how messengers signal the bone marrow to release adult stem cells to help in the repair of the injured tissue. Why this information is exciting for me to do a video is because I see stemcells as the best way of how to produce optimal health in your body. The way I look at it is that optimal health equals the number of healthy cells in your body and the only way the body repairs a damaged area is by creating and sending adult stem cells to that area. That #39;s why I #39;m introducing a stem cell product from a nutrition company who patented a stem cell enhancer which supports the release of adult stem cells. What will also excite you too is that Stemtech (the stemcell company) has also come out with two other products that will also optimize the circulation of these stem cells and other nutrients and aid in the ability for them to move and migrate into the affected tissue where they can transform and duplicate into fresh, healthy new cell tissue. So in my eyes having products like these will help anyone in my pursuit of health and wellness. I know it #39;s helping me strengthening my cells in my body after being diagnosed with chronic fatigue syndrome 20 plus years ago because I know how important nutrition and cell help to gain my ...From:Jennifer MarksViews:1 0ratingsTime:06:37More inHowto Style

View original post here:
What Are Stem Cells and Stem Cell Therapy Stemenhance - Video

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.

The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."

Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks

View original post here:
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy

Economic Times

Scientists pushing Genetic engineering ahead despite strong opposition to GM ... Economic Times Siva Reddy of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi is developing a better way of using agricultural waste. He is engineering plant choloroplasts - the machinery that fixes sunlight - to make cellulase, an ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGFJE--Z0rDZDh91cIf9TtL93hgxg&url=http://economictimes.indiatimes.com/news/news-by-industry/et-cetera/scientists-pushing-genetic-engineering-ahead-despite-strong-opposition-to-gm-crops/articleshow/17187696.cms

Farm Futures

Biotechnology Spurs Talk At Food Dialogues Farm Futures The third panel held at The Food Dialogues in New York City covered "Your Toughest Questions Answered on Biotechnology and Your Food." Moderated by Ali Velshi, CNN chief business correspondent, panelists included Dr. Bob Goldberg, plant molecular ... Final Panel Thoughts from USFRA Food DialoguesAgWired U.S. Farmers & Ranchers Alliance Names Nine Finalists For Its Faces Of ...Beef Magazine all 38 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEAejAacXhY7hSeE8gfa4WVMQbJGA&url=http://farmfutures.com/story.aspx/biotechnology-spurs-talk-food-dialogues-17/65030

Yoshiki Sasai is not just an ordinary tissue engineer who tries to coax stem cells to grow into fully formed bodily structures. It is true that Sasai has made his mark by taking on big projects like using stem cells to whip up a retina, cortical tissue and the cerebellum, involved with balance and movement. But his research has gone deeper by delving into the way stem cells organize themselves into complex structures under the influence of genes and the prenatal environment. Read a profile of Sasai here to accompany “ Grow Your Own Eye ,” Sasai’s own account of growing a retina in the November Scientific American .

[More]

Source:
http://rss.sciam.com/click.phdo?i=7291cadd43ac0cf30e9687431d559702

In the womb, a ball of identical cells gives rise to varied cell types that ultimately form highly ordered structures and then the full panoply of organs in the human body. The process advances according to an internal biological script that directs each fold and crease of tissue to assume exactly the proper shape and dimension.

[More]

Source:
http://rss.sciam.com/click.phdo?i=1e6abdd024c3b29c15070219c99ad16a

The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.

“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html

Geron Corp., which once pioneered human
embryonic stem cell research, is close to selling off its hESC business in a complicated deal involving two former CEOs of the company and
BioTime, Inc., of Alameda, Ca.

“ BioTime would contribute
to BAC $5 million in cash, $30 million of BioTime common
shares, warrants to purchase eight (8) million common shares
of BioTime at a pre-specified price, rights to use certain
human embryonic stem cell lines, and minority stakes in two of
BioTime’s subsidiaries. In addition, a private investor would
invest $5 million in cash in BAC. 

“Following consummation of the
potential transaction, Geron stockholders would receive
shares representing 21.4% of the common stock of BAC as well as
warrants to purchase 8 million shares of BioTime common
stock at a pre-specified price. BioTime would own
approximately 71.6%, and a private investor would own approximately
7.0% of the outstanding BAC common stock for their $5
million investment. BioTime would also receive
warrants that would enable it to increase its ownership in BAC by
approximately 2%, which would reduce the Geron stockholders’
ownership in BAC to 19.2%. BAC would also be committed to pay
to Geron royalties on the sale of products that are
commercialized in reliance upon Geron patents acquired by
BAC.”

“The offer couldn’t come at a
better time for Geron, which in recent months has started to feel
pressure from its shareholders to boost its stock price and move
products through the pipeline. Since last November, when the company
announced its decision to shutter its hESC and regenerative medicine
business and funnel its resources into developing telomerase-related
treatments for cancer, the stock price has dropped more than 50
percent to $1.30 a share. Geron claimed the move was simply to save
money, but many took the decision—which effectively terminated a
clinical trial of an hESC treatment for spinal cord injury—as a
setback for the entire field." 

News coverage of yesterday's
announcement was light. Here is a link to a piece by Ryan McBride on
Fierce Biotech.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/b-E7JaABIOI/geron-biotime-deal-moves-forward-with.html

Bone Marrow Stem cells for Rotator cuff Injury
George Ramsey Describes the road to recovery of his shoulder function using his own bone marrow stemcellsFrom:FLRegenerativeMedViews:0 0ratingsTime:01:55More inEducation

Read the rest here:
Bone Marrow Stem cells for Rotator cuff Injury - Video